EZH2 and myeloproliferative disorder: More importantly, we isolated HSPCs from distinct stages of leukemia development at disease initiation (2 weeks after pIpC-induced NRasG12D activation and/or EZH2 KO; T1, Fig. 1a), evolving MPN (2 months post-pIpC; T2), and blast phase post-MPN leukemia (4 months post-pIpC; T3).